The аntitumor effect of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol (chlonisol) on the growth of spontaneous mammary tumors in HER-2/neu transgenic mice

• Published in: Sibirskiĭ onkologicheskiĭ zhurnal Vol. 22; no. 3; pp. 76 - 82
• Main Authors: Alexandrov, V. A., Stukov, A. N., Zmitrichenko, Yu. G., Tochilnikov, G. V.
• Format: Journal Article
• Language: English; Russian
• Published: Russian Academy of Sciences, Tomsk National Research Medical Center 29-06-2023
• Subjects: 2-[3-(2-chloroethyl)-3-nitrosouriedo]-1; 3-propanediol; chlonisol; her2+ breast cancer; spontaneous tumors; transgenic mice
• ISSN: 1814-4861; 2312-3168
• DOI: 10.21294/1814-4861-2023-22-3-76-82

Background
. Current treatment of HER2-positive metastatic breast cancer (BC) is based on the use of anti-HER2 blockers as pathogenic drugs, as well as the search for the optimal combination of anticancer drugs with different mechanisms of action. The potential activity of chlonisol in HER2+ ВС is of great interesting. The aim of the study was to evaluate the antitumor effect of 2-[3-(2-chloroethyl)-3-nitrosouriedo]-1,3-propanediol (chlonisol) on the growth of spontaneous mammary tumors in HER-2/neu transgenic FVB/N mice.
Material and Methods
. A prospective study used 5-month-old female mice with HER2-positive mammary tumors. Of these animals, ten pairs with almost the same size of tumors were formed (respectively, for the control group and the chlonisol treatment group). Chlonisol was administered at a dose of 20 mg/kg intraperitoneally, once. The animals were followed up for 30 days.
Results
. In all ten pairs of mice, chlonisol showed a significant antitumor effect, up to a complete temporary regression of the tumor. When summing the comparative results of all ten pairs of animals, the inhibition of tumor growth (ITG) in the chlonisol treatment group was 90-97 % (p<0.0001), and the area under the kinetic curve of tumor growth was 13.6 times less than in the control group (p<0.0001), thus indicating a significant effect.
Conclusion
. Chlonisol has a high therapeutic activity by inhibiting the growth of spontaneous HER2-positive breast tumors in FVB/N mice.